BRPI0513812B8 - método para produzir uma composição líquida que compreende 13c-piruvato hiperpolarizado, composição, uso da mesma, radical, e, uso do radical - Google Patents
método para produzir uma composição líquida que compreende 13c-piruvato hiperpolarizado, composição, uso da mesma, radical, e, uso do radicalInfo
- Publication number
- BRPI0513812B8 BRPI0513812B8 BRPI0513812A BRPI0513812A BRPI0513812B8 BR PI0513812 B8 BRPI0513812 B8 BR PI0513812B8 BR PI0513812 A BRPI0513812 A BR PI0513812A BR PI0513812 A BRPI0513812 A BR PI0513812A BR PI0513812 B8 BRPI0513812 B8 BR PI0513812B8
- Authority
- BR
- Brazil
- Prior art keywords
- radical
- composition
- hyperpolarized
- pyruvate
- producing
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
- A61K49/1806—Suspensions, emulsions, colloids, dispersions
- A61K49/1815—Suspensions, emulsions, colloids, dispersions compo-inhalant, e.g. breath tests
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/05—Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fields; Measuring using microwaves or radio waves
- A61B5/055—Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fields; Measuring using microwaves or radio waves involving electronic [EMR] or nuclear [NMR] magnetic resonance, e.g. magnetic resonance imaging
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
- A61K49/10—Organic compounds
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N24/00—Investigating or analyzing materials by the use of nuclear magnetic resonance, electron paramagnetic resonance or other spin effects
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Health & Medical Sciences (AREA)
- Radiology & Medical Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Dispersion Chemistry (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Pathology (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Medical Informatics (AREA)
- High Energy & Nuclear Physics (AREA)
- Surgery (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Cosmetics (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Magnetic Resonance Imaging Apparatus (AREA)
- Rectifiers (AREA)
Abstract
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
NO20043229 | 2004-07-30 | ||
PCT/NO2005/000281 WO2006011809A1 (en) | 2004-07-30 | 2005-07-28 | Method of producing a composition, composition and its use |
Publications (3)
Publication Number | Publication Date |
---|---|
BRPI0513812A BRPI0513812A (pt) | 2008-05-13 |
BRPI0513812B1 BRPI0513812B1 (pt) | 2017-05-09 |
BRPI0513812B8 true BRPI0513812B8 (pt) | 2021-07-27 |
Family
ID=35058362
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0513812A BRPI0513812B8 (pt) | 2004-07-30 | 2005-07-28 | método para produzir uma composição líquida que compreende 13c-piruvato hiperpolarizado, composição, uso da mesma, radical, e, uso do radical |
Country Status (18)
Country | Link |
---|---|
US (2) | US20080095713A1 (pt) |
EP (1) | EP1797102B1 (pt) |
JP (2) | JP5367265B2 (pt) |
KR (2) | KR20070063504A (pt) |
CN (1) | CN101035796B (pt) |
AU (1) | AU2005267668B2 (pt) |
BR (1) | BRPI0513812B8 (pt) |
CA (1) | CA2575601C (pt) |
DK (1) | DK1797102T3 (pt) |
ES (1) | ES2545260T3 (pt) |
HK (1) | HK1107691A1 (pt) |
IL (1) | IL180897A (pt) |
MX (1) | MX2007001035A (pt) |
NZ (1) | NZ552898A (pt) |
PL (1) | PL1797102T3 (pt) |
RU (1) | RU2374252C2 (pt) |
WO (1) | WO2006011809A1 (pt) |
ZA (1) | ZA200701271B (pt) |
Families Citing this family (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0014463D0 (en) * | 2000-06-14 | 2000-08-09 | Nycomed Amersham Plc | NMR Method |
KR20070063504A (ko) * | 2004-07-30 | 2007-06-19 | 지이 헬스케어 에이에스 | 조성물의 제조 방법, 조성물 및 그의 용도 |
EP1954321B1 (en) * | 2005-12-01 | 2011-11-23 | Ge Healthcare As | Method of dynamic nuclear polarisation (dnp) using a trityl radical and a paramagnetic metal ion |
WO2007069909A2 (en) * | 2005-12-16 | 2007-06-21 | Ge Healthcare As | Method to produce hyperpolarised carboxylates of organic amines |
CN101415446A (zh) * | 2006-03-29 | 2009-04-22 | 通用电气医疗集团股份有限公司 | 生产超极化的羧酸盐和磺酸盐的方法 |
JP5269791B2 (ja) | 2006-08-30 | 2013-08-21 | ジーイー・ヘルスケア・アクスイェ・セルスカプ | 動的核分極(dnp)方法並びに該方法で使用するための化合物及び組成物 |
WO2008086534A1 (en) | 2007-01-11 | 2008-07-17 | Huntington Medical Research Institutes | Imaging agents and methods of use thereof |
US8731640B2 (en) | 2007-03-28 | 2014-05-20 | General Electric Company | Fluid path system for dissolution and transport of a hyperpolarized material |
US20080240998A1 (en) * | 2007-03-28 | 2008-10-02 | Urbahn John A | Fluid path system for dissolution and transport of a hyperpolarized material |
US7470813B2 (en) | 2007-03-30 | 2008-12-30 | Ge Healthcare Limited | Method for the production of pyruvic acid |
CA2683023C (en) * | 2007-05-17 | 2016-10-11 | General Electric Company | Mr methods of grading a tumor using an imaging medium that comprises hyperpolarized 13c-pyruvate |
US9227173B2 (en) | 2007-06-22 | 2016-01-05 | General Electric Company | Methods for dynamic filtration of pharmaceutical products |
EP2170407A2 (en) * | 2007-07-26 | 2010-04-07 | GE Healthcare UK Limited | Imaging medium comprising hyperpolarised 13c-lactate and use thereof |
EP2902041A1 (en) | 2007-12-19 | 2015-08-05 | GE Healthcare Limited | Composition and method for generating a metabolic profile using 13C-MR detection |
ES2379143T3 (es) * | 2007-12-21 | 2012-04-23 | Ge Healthcare Limited | Agente de obtención de imágenes por RM, medio de obtención de imágenes y procedimientos para la obtención de imágenes en los que se utiliza dicho medio de obtención de imágenes |
WO2009129265A1 (en) | 2008-04-14 | 2009-10-22 | Huntington Medical Research Institutes | Methods and apparatus for pasadena hyperpolarization |
US8763410B2 (en) | 2008-04-21 | 2014-07-01 | General Electric Company | Method and apparatus for the dissolution and filtration of a hyperpolarized agent with a neutral dissolution media |
CN102083470B (zh) | 2008-05-02 | 2015-05-20 | 通用电气公司 | 应用超极化13c-丙酮酸盐,通过13c-mr检测测定丙氨酸转氨酶(alt)活性的方法 |
RU2543704C2 (ru) | 2009-04-02 | 2015-03-10 | ДжиИ ХЕЛТКЕР ЛИМИТЕД | Применение магнитно-резонансной визуализирующей среды, содержащей гиперполяризованный 13с-пируват, для обнаружения воспаления или инфекции |
JP5744032B2 (ja) | 2009-09-10 | 2015-07-01 | ジーイー・ヘルスケア・リミテッド | 過分極13c−フルクトースを用いる13c−mr検出 |
DE102009054956A1 (de) * | 2009-12-18 | 2011-06-22 | Siemens Aktiengesellschaft, 80333 | Magnetresonanztomographie-Bildgebung |
CN102892434B (zh) | 2010-04-08 | 2014-11-19 | 伯拉考成像股份公司 | 制备超极化底物的方法和mri方法 |
US9259490B2 (en) | 2010-05-03 | 2016-02-16 | Ge Healthcare Limited | Hyperpolarized lactate contrast agent for determination of LDH activity |
US20130149250A1 (en) * | 2011-06-23 | 2013-06-13 | The Regents Of The University Of California | Hyperpolarized agents for mri characterization of redox systems in vivo |
US9511154B2 (en) | 2011-10-12 | 2016-12-06 | Bracco Imaging S.P.A. | Process for the preparation of hyperpolarized derivatives for use in MRI analysis |
EP2788035B1 (en) | 2011-12-05 | 2016-03-09 | Bracco Imaging S.p.A | Composition comprising acetic anhydride and a gadolinium complex, and method for the use in hyperpolarisation mri analysis |
JP6507101B2 (ja) | 2013-01-31 | 2019-04-24 | ブラッコ・イメージング・ソシエタ・ペル・アチオニBracco Imaging S.P.A. | Mrにおける代謝マーカーとしての過分極エステル |
WO2015000838A1 (en) | 2013-07-01 | 2015-01-08 | Bracco Imaging Spa | Hyperpolarized 1-13c-1,1-bis(acetoxy(methyl))-2,2'-cyclopropane as metabolic marker for mr |
US9874622B2 (en) | 2013-09-27 | 2018-01-23 | General Electric Company | Hyperpolarized media transport vessel |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IE61448B1 (en) | 1987-06-23 | 1994-11-02 | Hafslund Nycomed Innovation | Improvements in and relating to magnetic resonance imaging |
GB8817137D0 (en) | 1988-07-19 | 1988-08-24 | Nycomed As | Compositions |
EP0515458B1 (en) | 1990-02-12 | 1995-08-23 | Nycomed Innovation AB | Triarylmethyl radicals and the use of inert carbon free radicals in mri |
DK0662004T3 (da) | 1991-08-09 | 1998-10-19 | Nycomed Innovation Ab | Anvendelse af stabile frie radikaler ved magnetiskresonans-billeddannnelse |
US5728370A (en) | 1993-04-02 | 1998-03-17 | Nycomed Imaging As | Free Radicals |
EP0871896B1 (en) | 1995-09-08 | 2002-01-30 | Nycomed Imaging AS | A method of determining oxygen concentration in a sample |
WO1998039277A1 (en) | 1997-03-06 | 1998-09-11 | Nycomed Imaging As | Triarylmethyl free radicals as image enhancing agents |
AU8119298A (en) | 1997-06-19 | 1999-01-04 | Nycomed Imaging As | Overhauser magnetic resonance imaging (ormi) method comprising ex vivo polarization of a magnetic resonance (mr) imaging agent |
US6278893B1 (en) * | 1998-01-05 | 2001-08-21 | Nycomed Imaging As | Method of magnetic resonance imaging of a sample with ex vivo polarization of an MR imaging agent |
US6232497B1 (en) | 1998-12-23 | 2001-05-15 | Skw Trostberg Aktiengesellschaft | Method for producing alkali metal and alkaline earth metal pyruvates |
GB0014463D0 (en) * | 2000-06-14 | 2000-08-09 | Nycomed Amersham Plc | NMR Method |
CN100392422C (zh) | 2000-11-03 | 2008-06-04 | 通用电气医疗集团股份有限公司 | 为nmr分析溶解超极化固体材料的方法和装置 |
US6617169B2 (en) * | 2001-03-30 | 2003-09-09 | Mclean Hospital Corporation | Two-dimensional MR spectroscopy techniques |
US6486671B1 (en) * | 2001-05-14 | 2002-11-26 | Ge Medical Systems Global Technologies Company Llc | MRI image quality improvement using matrix regularization |
US6958244B2 (en) * | 2002-04-12 | 2005-10-25 | Bruker Biospin Corp. | Low-conductivity buffers for magnetic resonance measurements |
KR20070063504A (ko) * | 2004-07-30 | 2007-06-19 | 지이 헬스케어 에이에스 | 조성물의 제조 방법, 조성물 및 그의 용도 |
WO2006011811A2 (en) * | 2004-07-30 | 2006-02-02 | Ge Healthcare As | Radicals and their use as paramagnetic agents in a dynamic nuclear polarisation process |
-
2005
- 2005-07-28 KR KR1020077004779A patent/KR20070063504A/ko not_active Application Discontinuation
- 2005-07-28 ES ES05771194.7T patent/ES2545260T3/es active Active
- 2005-07-28 BR BRPI0513812A patent/BRPI0513812B8/pt not_active IP Right Cessation
- 2005-07-28 DK DK05771194.7T patent/DK1797102T3/en active
- 2005-07-28 PL PL05771194T patent/PL1797102T3/pl unknown
- 2005-07-28 AU AU2005267668A patent/AU2005267668B2/en not_active Ceased
- 2005-07-28 WO PCT/NO2005/000281 patent/WO2006011809A1/en active Application Filing
- 2005-07-28 EP EP05771194.7A patent/EP1797102B1/en active Active
- 2005-07-28 RU RU2007102843/04A patent/RU2374252C2/ru not_active IP Right Cessation
- 2005-07-28 US US11/572,679 patent/US20080095713A1/en not_active Abandoned
- 2005-07-28 CN CN2005800334196A patent/CN101035796B/zh active Active
- 2005-07-28 CA CA2575601A patent/CA2575601C/en active Active
- 2005-07-28 JP JP2007523504A patent/JP5367265B2/ja active Active
- 2005-07-28 MX MX2007001035A patent/MX2007001035A/es active IP Right Grant
- 2005-07-28 KR KR1020137005588A patent/KR101475635B1/ko not_active IP Right Cessation
- 2005-07-28 NZ NZ552898A patent/NZ552898A/en not_active IP Right Cessation
- 2005-07-28 US US11/572,671 patent/US9023320B2/en active Active
-
2007
- 2007-01-23 IL IL180897A patent/IL180897A/en active IP Right Grant
- 2007-02-13 ZA ZA200701271A patent/ZA200701271B/en unknown
- 2007-12-05 HK HK07113302.9A patent/HK1107691A1/xx not_active IP Right Cessation
-
2012
- 2012-07-12 JP JP2012156109A patent/JP5745470B2/ja active Active
Also Published As
Publication number | Publication date |
---|---|
IL180897A (en) | 2010-11-30 |
PL1797102T3 (pl) | 2015-10-30 |
WO2006011809A1 (en) | 2006-02-02 |
NZ552898A (en) | 2011-02-25 |
CN101035796A (zh) | 2007-09-12 |
JP2012236832A (ja) | 2012-12-06 |
EP1797102A1 (en) | 2007-06-20 |
JP5745470B2 (ja) | 2015-07-08 |
ZA200701271B (en) | 2008-05-28 |
EP1797102B1 (en) | 2015-05-27 |
KR20130028989A (ko) | 2013-03-20 |
RU2374252C2 (ru) | 2009-11-27 |
RU2007102843A (ru) | 2008-09-10 |
KR20070063504A (ko) | 2007-06-19 |
KR101475635B1 (ko) | 2014-12-22 |
CA2575601C (en) | 2013-05-28 |
ES2545260T3 (es) | 2015-09-09 |
US9023320B2 (en) | 2015-05-05 |
US20080213186A1 (en) | 2008-09-04 |
AU2005267668A1 (en) | 2006-02-02 |
CN101035796B (zh) | 2011-06-22 |
CA2575601A1 (en) | 2006-02-02 |
JP2008508266A (ja) | 2008-03-21 |
BRPI0513812A (pt) | 2008-05-13 |
MX2007001035A (es) | 2007-07-11 |
IL180897A0 (en) | 2007-07-04 |
AU2005267668B2 (en) | 2011-10-20 |
US20080095713A1 (en) | 2008-04-24 |
DK1797102T3 (en) | 2015-08-24 |
BRPI0513812B1 (pt) | 2017-05-09 |
HK1107691A1 (en) | 2008-04-11 |
JP5367265B2 (ja) | 2013-12-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0513812B8 (pt) | método para produzir uma composição líquida que compreende 13c-piruvato hiperpolarizado, composição, uso da mesma, radical, e, uso do radical | |
BR112012022797A2 (pt) | composição farmacêutica resistente a álcool, e, método para tratar uma doença com uma formulação de agente ativo resistente a álcool | |
BR112018006259A2 (pt) | "adjunto compressível com estruturas de suporte intermediárias" | |
PE20142371A1 (es) | Combinacion farmaceutica de 3-(3-dimetilamino-1-etil-2-metil-propil)-fenol y un antiepileptico | |
BRPI0520669A2 (pt) | dosagem farmacêutica que reduz o efeito do alimento encontrado para administração de atorvastatina | |
BRPI0612674B8 (pt) | preparação farmacêutica, uso de um antagonista do receptor de angiotensina ii e um bloqueador do canal de cálcio | |
CL2008000691A1 (es) | Compuestos derivados de dihidro y tetrahidro oxazolopirimidinonas sustituidas; composicion farmaceutica que comprende a dichos compuestos; y su uso para el tratamiento de la esquizofrenia, epilepsia, entre otras enfermedades. | |
HN2006000971A (es) | Metodos para preparar composiciones o formas de dosificacion que comprenden un agonista grp119 que tiene el efecto de un secretagogo glp-1 | |
ECSP067062A (es) | Derivados de pirazol, composiciones que contienen dichos compuestos y procedimientos de uso | |
DOP2010000304A (es) | Composiciones y metodos de preparacion y uso de las mismas | |
BR112012006692A2 (pt) | composição farmacêutica compreendendo ácido graxo de omega-3 e um derivado de hidróxi de uma estatina e métodos de uso das mesmas | |
CU23779B7 (es) | Compuestos de pirazolina y su uso y composiciones farmacéuticas | |
CL2007001698A1 (es) | Composicion inmunogenica que comprende los lipooligosacaridos meningococicos (los) de inmunotipos l2 y l3 de cepas neissericas; composicion de vacuna que la comprende; procedimiento de preparacion; y su uso para la prevencion o tratamiento de enfermedades causadas por uno o mas serogrupos de n. meningitidis. | |
AR053026A1 (es) | Composiciones de anticuerpos anti factor de estimulacion de colonias de macrofagos (anti-m csf) | |
BRPI0817482B8 (pt) | uso de um anticorpo do receptor da interleucina-6 (il-6) no tratamento da doença do enxerto versus hospedeiro (gvhd) | |
AR047841A1 (es) | Metodos y composiciones para el tratamiento de transtornos inmunoinflamatorios | |
BRPI0507684A (pt) | agentes de contraste para formação de imagem de perfusão miocárdica | |
GT200900201A (es) | Formulaciones para el tratamiento del cáncer. | |
CL2012002551A1 (es) | Combinacion farmaceutica que comprende por lo menos un 3-(3-dimetilamino-1-etil-2-metil-propil)-fenol de fórmula (i) y por lo menos un antagonista de nmda; composicion farmaceutica; y uso para el tratamiento del dolor. | |
ECSP088296A (es) | Compuestos terapéuticos | |
BR112018073298A2 (pt) | cápsula, suspensão de cápsula, mistura, uso das cápsulas e método para reduzir a nitrificação | |
CL2006002332A1 (es) | Metodo para preparar una composicion medica que comprende preparar una composicion para tratamiento y agregar al menos un agente a dicha composicion, en donde los agentes tienen la propiedad de aumentar o al menos mantener la viscosidad de la composi | |
CY1118835T1 (el) | Αντισωμα anti-fgf23 και φαρμακευτικη συνθεση που το περιλαμβανει | |
BR112012013164A2 (pt) | composições farmacêuticas para o estímulo de células-tronco | |
CL2013003307A1 (es) | Agente que comprende ciazofamida o fenamidona; y su uso para tratar micosis en peces e invertebrados en todos sus estadios de desarrollo causada por hongos de los generos saprolegnia, achlya y aphanomyces (div.sol.n°1056-08). |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B07G | Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette] |
Free format text: NOTIFICACAO DE DEVOLUCAO DO PEDIDO POR NAO SE ENQUADRAR NO ART. 229-C DA LPI. |
|
B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
B15K | Others concerning applications: alteration of classification |
Ipc: C07D 519/00 (2006.01), A61B 5/055 (2006.01), A61K |
|
B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] | ||
B21F | Lapse acc. art. 78, item iv - on non-payment of the annual fees in time |
Free format text: REFERENTE A 16A ANUIDADE. |
|
B16C | Correction of notification of the grant [chapter 16.3 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 28/07/2005, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO |
|
B24J | Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12) |
Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2630 DE 01-06-2021 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |